Bladder Cancer

Patients who experience side effects due to immune checkpoint inhibitors are 80% more likely to go to the emergency room and have 30% higher monthly medical costs, compared to patients who did not have side effects.

A phase 1b trial started to study the effects of fosciclopirox in patients with newly diagnosed and recurrent bladder cancer.

The PRESERVE 3 trial began this summer to determine efficacy of using Cosela with platinum-based chemotherapy in patients with metastatic bladder cancer.

Treatments for bladder, colorectal and prostate cancer may cause sexual dysfunction in men. Here, an expert provides insight into how patients and survivors may improve their sexual health.

A bladder cancer survivor discusses the importance of World Ostomy Day and shares her own ostomy story.

It is important that the whole community understand that basic research and clinical trials can continue to improve outcomes for patients with genitourinary cancer.

In this special issue of CURE®, we spoke with patients and health care providers about fertility issues, treatment advancements and other topics related to kidney, prostate, testicular and bladder cancers.

The novel drug N-803 boosted response to Bacille Calmette-Guérin therapy in patients with non-muscle invasive bladder cancer, a study showed.

Clinical trials that are designed to ask patients with bladder, kidney and prostate cancer about their smoking status may help patients better understand what to expect from their treatment based on their smoking habits.

Patients with Bacillus Calmette Guérin-unresponsive carcinoma in-situ will be treated at the University of Chicago in a Theralase study.

Keytruda is now indicated for the treatment of locally advanced or metastatic urothelial carcinoma, a type of bladder cancer, although an unmet need remains in the treatment of these patients.

A recently approved antibody-drug conjugate provides another much-needed treatment choice for patients with locally advanced and metastatic urothelial cancer.

Preliminary results of the phase 2 trial assessing the safety and efficacy of Cosela with gemcitabine/platinum-based chemotherapy and Bavencio maintenance therapy for metastatic bladder cancer are expected to be released in the second half of 2022.

The FDA granted approval to Opdivo as an adjuvant treatment in patients with high-risk urothelial carcinoma.

Intravesical therapy for patients with non-muscle invasive bladder cancer was found to have an impact on patients’ social, emotional and physical health.

Smoking cigarettes could lead to a four-fold increased risk of recurrence in patients with a previous diagnosis of non-muscle invasive bladder cancer.

An analysis showed that glycemic index – but not glycemic load or total carbohydrate intake – significantly increased the risk of developing bladder cancer.

Approximately 18 months after granting Padcev an accelerated approval, the Food and Drug Administration granted a regular approval to the treatment for certain previously treated patients with locally advanced or metastatic urothelial carcinoma.

Agent Orange exposure impacted millions of U.S. military personnel during the Vietnam War. The chemical may have led to bladder cancer diagnoses later in life.

Keytruda plus gemcitabine and higher doses of radiotherapy showed promising efficacy and safety results in patients with muscle-invasive bladder cancer.

Patients who tested positive for the biomarker circulating tumor DNA (ctDNA) had improved disease-free and overall survival after receiving Tecentriq.

The study’s lead author noted that the data support giving patients with advanced bladder cancer chemotherapy to get control of the disease and then maintaining that control with maintenance Bavencio.

Some of the most popular YouTube videos about bladder cancer are of poor quality, spread misinformation and have commercial bias.

A retirement counselor with bladder cancer shares the story of his diagnosis and his thoughts on treatment.

A roundup of some of CURE®’s latest news and updates for patients with bladder cancer in honor of Bladder Cancer Awareness Month this May.

FDA committee members recently voted in favor of upholding Tecentriq’s accelerated approval indication for the first-line treatment of certain adults with locally advanced or metastatic urothelial carcinoma who are ineligible for standard chemotherapy.

Several factors were associated with patients undergoing radical nephrectomy compared with radical nephroureterectomy including Black race, large tumors, advanced tumor stage and high-grade tumors.

Trodelvy has received accelerated approval from the FDA for the treatment of patients with advanced urothelial cancer.

Adjusting the dose of cisplatin, when added to regular doses of Abraxane and gemcitabine, led to similar survival rates when treating patients with advanced/metastatic urothelial carcinoma, which may help to address issues commonly seen with patients who cannot tolerate cisplatin such as renal dysfunction.

If patients were receiving Tecentriq for prior platinum-based treated metastatic urothelial carcinoma, they should discuss next best steps with their health care providers.